[CAS NO. 138402-11-6] Irbesartan

Name: Irbesartan
Brand: Arctom Scientific
SKU: HY-B0202

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [138402-11-6]

Store

Catalog

HY-B0202

Brand

MCE

CAS

138402-11-6

DESCRIPTION [138402-11-6]

Overview

MDL	MFCD00864464
Molecular Weight	428.53
Molecular Formula	C25H28N6O
SMILES	O=C1N(CC2=CC=C(C3=C(C4=NN=NN4)C=CC=C3)C=C2)C(CCCC)=NC15CCCC5

For research use only. We do not sell to patients.

3 Publications Citing Use of MCE

Summary

Irbesartan (SR-47436) is an orally active Ang II type 1 (AT1) receptor blocker (ARB) . Irbesartan can relax the blood vessels, low blood pressure and increase the supply of blood and oxygen to the heart. Irbesartan can be used for the research of high blood pressure, heart failure, and diabetic kidney disease ^[1] .

In Vitro

Irbesartan (20 μM, 3 h) reduces Th22 cells chemotaxis in vitro ^[1] .
Irbesartan (0 μM, 20 μM, 40 μM and 60 μM) suppresses Th22 cells differentiation in vitro ^[1] .
Irbesartan (20 μM) inhibits Th22 cells related proinflammatory response of TECs in vitro ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[1]

Cell Line:	CD4+ T cells
Concentration:	0, 20, 40 and 60 μM
Incubation Time:	48 h
Result:	Exerted no obvious effect on viability of CD4 ⁺ T cells.

In Vivo

Irbesartan (oral gavage; 50 mg/kg/d; once daily) reduces Th22 lymphocytosis and serum IL-22 level in Ang II-infused mice ^[1] .
Irbesartan (oral gavage; 50 mg/kg/d; once daily) exerts obvious renoprotective effects ^[1] .
Irbesartan (oral gavage; 50 mg/kg/d; once daily) relieves systemic inflammation and renal fibrosis in hypertension mice induced by Ang II ^[1] .
Irbesartan hydrochloride (20 μM; for 3 h) can attenuate Th22 cells recruitment and IL-22 secretion, which might be through inhibiting chemotaxis in hypertensive renal injury mice ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6 mice ^[1]
Dosage:	50 mg/kg
Administration:	oral gavage; 50 mg/kg/d; once daily
Result:	Displayed low Th22 cells and IL-22, exerted similar inhibitory effect on Th1 cell proportion and displayed decreased IL-22 level in kidney. Prevented BP elevation markedly and decreased urinary albumin/creatinine ratio, BUN and Scr. Repressed the expression of IL-1β, IL-6, TNF-α, α-SMA, FN and Col I and diminished the extent of fibrosis.

Animal Model:	C57BL/6 mice ^[1]
Dosage:	20 μM
Administration:	20 μM; for 3 h
Result:	Downregulated renal CCL20, CCL22 and CCL27 concentrations.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01968759	Mario Negri Institute for Pharmacological Research	Chronic Kidney Disease	October 2013	Phase 2
NCT00657059	Sun Yat-sen University	IgA Nephropathy	September 2007	Phase 3
NCT05243199	Ruijin Hospital	CKD5 Stage Dialysis\|Heart Failure	August 1, 2020	Phase 4
NCT00352560	Bristol-Myers Squibb\|Sanofi	Atrial Fibrillation	July 2006	Phase 3
NCT00517322	Università degli Studi dell´Insubria	Left Atrial Volume\|Hypertensive Heart Disease\|Antihypertensive Drugs\|Diastolic Function\|Renin Angiotensin System	August 2007	Phase 4
NCT03016832	Jiangsu Famous Medical Technology Co., Ltd.	Diabetic Kidney Disease	January 2017	Early Phase 1
NCT00529750	Sanofi	Hypertension	July 2002	Phase 4
NCT00708344	Sanofi	Hypertension	June 2008	Phase 4
NCT00389168	Karolinska Institutet\|Bristol-Myers Squibb\|Sanofi\|Swedish Heart Lung Foundation	Hypertension	April 1995	Phase 2\|Phase 3
NCT00347087	Charite University, Berlin, Germany\|Bristol-Myers Squibb	Chronic Heart Failure	July 2004	Phase 4
NCT00350038	Sanofi\|Bristol-Myers Squibb	Hypertension\|Dyslipidemia	February 2005	Phase 4
NCT00564187	Sanofi\|Bristol-Myers Squibb	Hypertension	February 2003	Phase 4
NCT00362037	Sanofi\|Bristol-Myers Squibb	Hypertension	March 2006	Phase 4
NCT03476603	Norwegian University of Science and Technology\|St. Olavs Hospital\|Volvat Medisinsk Senter Stokkan\|Namsos Hospital\|Alesund Hospital	Obesity, Morbid	November 2, 2016
NCT02380625	Clinical Research Management, Inc.\|Bill and Melinda Gates Foundation\|Duke University\|University of Sierra Leone\|Syneos Health\|University of North Carolina	Ebola Virus Disease	April 2015	Phase 1\|Phase 2
NCT03762850	Travere Therapeutics, Inc.	Immunoglobulin A Nephropathy	December 11, 2018	Phase 3
NCT00443612	Sanofi	Hypertension	September 2006	Phase 4
NCT05476354	Handok Inc.	Essential Hypertension	August 2022	Phase 3
NCT00263003	Sanofi	Hypertension	June 2005	Phase 3
NCT00110422	Bristol-Myers Squibb\|Sanofi	Metabolic Syndrome\|Hypertension	November 2005	Phase 4
NCT01238705	LanZhou University	Hypertension\|Sexual Dysfunction	April 2008	Phase 4
NCT00283036	Sanofi\|Bristol-Myers Squibb	Hypertension	April 2005	Phase 4
NCT03147677	The Third Xiangya Hospital of Central South University	Type 2 Diabetic Nephropathy	July 28, 2016	Phase 4
NCT00660309	Novartis	Type 2 Diabetes Mellitus	April 2008	Phase 4
NCT00561964	Sanofi\|Bristol-Myers Squibb	Hypertension	January 2004	Phase 3
NCT00095394	Bristol-Myers Squibb\|Sanofi	Hypertension	September 2004	Phase 3
NCT00152698	University of Erlangen-Nürnberg Medical School\|Bristol-Myers Squibb	Hypercholesterolemia	November 2009	Phase 3
NCT00185055	Daiichi Sankyo, Inc.	Healthy	November 2004	Phase 4
NCT05056727	AstraZeneca	Renal Insufficiency, Chronic\|Hyperkalemia	September 30, 2021	Phase 3
NCT02644486	Zhi-Hong Liu, M.D.\|Nanjing University School of Medicine	Obesity and Glomerulopathy	January 2016	Not Applicable
NCT00317915	Steno Diabetes Center Copenhagen\|Bristol-Myers Squibb\|Sanofi-Synthelabo	Type 2 Diabetes\|Microalbuminuria\|Hypertension		Phase 3
NCT05297929	The Affiliated Hospital of Qingdao University	Irbesartan Tablets (0.15g+Tablet)\|Under Fasted Condition\|Under Fed Condition\|Bioequivalence	February 17, 2022	Phase 1
NCT00334581	Sanofi\|Bristol-Myers Squibb	Hypertension	May 2006	Phase 4
NCT00320879	Steno Diabetes Center Copenhagen	Type 2 Diabetes\|Microalbuminuria	September 2003	Phase 4
NCT00249795	Sanofi\|Bristol-Myers Squibb	Atrial Fibrillation\|Cardiovascular Disease	June 2003	Phase 3
NCT01613118	Travere Therapeutics, Inc.	Focal Segmental Glomerulosclerosis	March 2014	Phase 2
NCT00549133	Sanofi	Hypertension\|Diabetes Mellitus Type 2	October 2003	Phase 4
NCT01712100	Roxane Laboratories\|West-Ward Pharmaceutical	Hypertension	August 2007	Not Applicable
NCT00095550	Bristol-Myers Squibb\|Sanofi	Hypertension	October 2004	Phase 3
NCT05475665	Handok Inc.	Essential Hypertension	July 14, 2022	Phase 3
NCT01712139	Roxane Laboratories\|West-Ward Pharmaceutical	Hypertension	September 2007	Not Applicable
NCT00095290	Bristol-Myers Squibb\|Sanofi	Albuminuria	September 2004	Phase 4
NCT00847834	Sanofi	Hypertension	December 2003	Phase 4
NCT02386293	Augusta University	Hypertension\|Obesity\|Stress, Psychological\|Blood Pressure	April 2014	Phase 2
NCT01360710	Baker Heart and Diabetes Institute	Abdominal Obesity\|Hypertension	January 2012	Phase 4
NCT00613496	University of Magdeburg\|Sanofi	Persistent Atrial Fibrillation	May 2009	Phase 4
NCT00180024	Technische Universität Dresden	Healthy Subjects	January 2002	Not Applicable
NCT00933231	Astellas Pharma Inc\|Astellas Pharma Canada, Inc.	Kidney Transplantation	August 17, 2009	Phase 3
NCT02721342	Mario Negri Institute for Pharmacological Research	Chronic Kidney Disease	June 2009
NCT01949233	University of Oxford\|Oxford University Hospitals NHS Trust	Marfan Syndrome	October 2013	Phase 2
NCT01825850	LG Life Sciences	Healthy	June 2013	Phase 1
NCT01992796	University of Salerno\|Federico II University	Severe Sepsis	January 2014	Phase 3
NCT00791830	University of Aarhus	Kidney Failure, Chronic	April 2009	Phase 3
NCT00957554	Sanofi	Hypertension	July 2009	Phase 3
NCT00950066	Sanofi	Hypertension	July 2009	Phase 2
NCT02842359	Sanofi	Type 2 Diabetes Mellitus	August 23, 2016	Phase 4
NCT00362258	Sanofi\|Bristol-Myers Squibb	Hypertension	February 2006	Phase 4
NCT00794963	Northwell Health	Metabolic Syndrome	November 2008	Not Applicable
NCT00296218	Sanofi\|Bristol-Myers Squibb	Myocardial Ischemia\|Hypertension	February 2006	Phase 3
NCT00154024	Technische Universität Dresden	Healthy Subjects	March 2003	Not Applicable
NCT00742066	Maastricht University Medical Center	Hypertension\|Insulin Resistance\|Microcirculation	March 2008	Not Applicable
NCT00987662	Aristotle University Of Thessaloniki	Obesity\|Hypertension	January 2012	Phase 4
NCT00335673	Sanofi\|Bristol-Myers Squibb	Hypertension	February 2006	Phase 4
NCT01519297	Brigham and Women´s Hospital	Preeclampsia\|Pregnancy Induced Hypertension	May 2012	Not Applicable
NCT00265642	ANRS, Emerging Infectious Diseases\|Sanofi	Hepatitis C, Chronic	October 2006	Phase 3
NCT03493685	Travere Therapeutics, Inc.	Focal Segmental Glomerulosclerosis	April 17, 2018	Phase 3
NCT01442987	Hanmi Pharmaceutical Company Limited	Hypertension\|Hyperlipidemia	May 2011	Phase 3
NCT00125645	University of Southern Denmark\|Bristol-Myers Squibb	Myocardial Infarction	March 1, 2005	Phase 4
NCT00005010	National Institute of Allergy and Infectious Diseases (NIAID)	End-Stage Renal Disease\|Chronic Allograft Nephropathy		Phase 3
NCT00265967	Sanofi\|Bristol-Myers Squibb	Hypertension	September 2005	Phase 4
NCT03934307	Alnylam Pharmaceuticals	Hypertension	May 1, 2019	Phase 1
NCT02597361	Assistance Publique - Hôpitaux de Paris\|Ministry of Health, France	Ehlers-Danlos Syndrome, Vascular Type	January 2016	Phase 3
NCT01712113	Roxane Laboratories\|West-Ward Pharmaceutical	Hypertension	August 2007	Not Applicable
NCT00225667	Connolly, Stuart, M.D.\|Sanofi\|Bristol-Myers Squibb	Atrial Fibrillation\|Hypertension	December 2005	Phase 3
NCT00535925	University of Campania Luigi Vanvitelli	Diabetic Nephropathy	October 2005	Phase 4
NCT01712126	Roxane Laboratories\|West-Ward Pharmaceutical	Hypertension	September 2007	Not Applicable
NCT00562809	Sanofi\|Bristol-Myers Squibb	Hypertension	July 2003	Phase 4
NCT00635232	Ligand Pharmaceuticals	Hypertension	March 2008	Phase 2
NCT00106561	Melbourne Health	Kidney Disease\|Diabetic Nephropathy\|Glomerulonephritis\|Proteinuria	January 2002	Phase 2\|Phase 3
NCT00264212	Sanofi\|Bristol-Myers Squibb	Hypertension	August 2004	Phase 4
NCT00095238	Bristol-Myers Squibb\|Sanofi	Congestive Heart Failure	June 2002	Phase 3
NCT01858610	Damanhour University	Healthy	March 2013	Not Applicable
NCT01447797	Hanmi Pharmaceutical Company Limited	Healthy	September 2011	Phase 1
NCT00171080	Novartis	Hypertension	April 2004	Phase 3

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 233.36 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3336 mL	11.6678 mL	23.3356 mL
5 mM	0.4667 mL	2.3336 mL	4.6671 mL
10 mM	0.2334 mL	1.1668 mL	2.3336 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (5.83 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (5.83 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (5.83 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-

1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-

2-Butyl-3-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one

SR 47436

2-Butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one

Irbesartan

BMS 186295

Avapro

Aprovel

Karvea

2-Butyl-3-[[2′-(tetrazol-5-yl)biphenyl-4-yl]-methyl]-1,3-diazaspiro[4.4]non-1-en-4-one

Irbetan

Irbest

Kansartan

X-Tension

3-Butyl-2-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-2,4-diazaspiro[4.4]non-3-en-1-one

2-Butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one

2-Butyl-3-[2′-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[4.4]non-1-en-4-one

Sabervel